Neurofibroma

Neurofibromas are a common type of peripheral nerve sheath tumour that develops on peripheral nerves that contain fibrous or connective tissue. They are generally benign, solitary and sporadic (develop randomly without a genetic predisposition).

Peripheral nerve sheath tumours (PNSTs) are tumours that arise from the protective layer of peripheral nerves. More specifically, they develop from nerve sheaths, which are layers of myelin and connective tissue that provide insulation to nerve fibres within the nervous system.

The nervous system is made up of two primary components: the central nervous system (CNS), and the peripheral nervous system (PNS). The CNS is made up of the brain and spinal cord, and is responsible for all sensory and motor functions in the body. The PNS encompasses all nerves outside of the CNS, and is responsible for all involuntary functions in the body. The PNS is further subdivided into the autonomic nervous system (ANS) and the somatic nervous system (SNS). The ANS controls involuntary processes and glands, such as heart rate, blood pressure, respiration, and digestion. Comparatively, the SNS is responsible for voluntary and involuntary muscle movements, as well as transmitting sensory information to the CNS.

Neurofibromas are generally diagnosed equally among the sexes, and are generally diagnosed in people between the ages of 20-40. However, anyone can develop this disease.

Types of Neurofibromas

There are four primary types of neurofibroma, which are classified by the types of cells they develop from.

Intraneural Neurofibroma

Intraneural neurofibromas are the most common subtype of neurofibroma, and is categorised by the tumour developing inside the centre of the nerve. These tumours are generally found in patients between the ages of 20-30, and can be localised and/or nodular. Intraneural neurofibromas are generally benign, and can have a good prognosis.

Localised/Nodular Cutaneous Neurofibroma

Localised and nodular cutaneous neurofibromas are a less common subtype of neurofibroma that develops within the dermis (middle layer of the skin) and subcutaneous tissue (fatty tissue layer beneath the skin). These tumours are generally found in patients between the ages of 20-30, and can develop in any area of the body. Localised and nodular cutaneous neurofibromas are often benign, and can have a good prognosis.

Diffuse Cutaneous Neurofibroma

Diffuse cutaneous neurofibroma are a rare subtype of neurofibroma that develops within subcutaneous tissue beneath the skin. However, unlike localised cutaneous neurofibroma, these tumours are not well contained (or diffuse), and are generally diagnosed in children and young adults. Diffuse cutaneous neurofibromas are commonly misdiagnosed as plexiform neurofibroma, however these tumours are less likely to become cancerous. These tumours are generally benign, and can have a good prognosis.

Plexiform Neurofibroma

Plexiform neurofibromas are a rare subtype of neurofibroma that develops within the subcutaneous tissue beneath the skin, and are commonly confused with diffuse cutaneous neurofibromas. These tumours are generally diagnosed in early childhood, and have a strong association to neurofibromatosis type 1 (NF1). Plexiform neurofibromas tend to develop deeper into nerves and plexuses, and have a higher chance of undergoing a malignant transformation.

Treatment

When cancers are detected, they are staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you. However, as the neurofibromas are considered benign, these tumours are generally considered low-grade and not staged.

Once your tumour has been diagnosed, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment is dependent on several factors, including location, age, stage of disease and overall health.

Treatment options for neurofibromas may include:

  • Surgery to remove as much of the tumour as possible.
  • Watch and wait.
  • Radiation therapy.
  • Clinical trials.
  • Palliative care.

Risk factors

While the cause of neurofibromas remain unknown, the following factors may increase the likelihood of developing the disease.

  • Having a family history of the disease.
  • Being diagnosed with the condition neurofibromatosis type 1 (NF1).

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

Neurofibromas may appear asymptomatic in the early stages of disease. If the tumour becomes malignant, or if the tumour is pressing on a nerve, you may experience:

  • Pain in the affected area.
  • Numbness and/or tingling in the affected area.
  • Weakness and/or loss of function in affected area.
  • Small, pea-shaped lumps under the skin.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a neurofibroma, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Neurological examination.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
  • Blood tests.
  • Electromyogram (EMG).
  • Nerve conduction studies.
  • Biopsy.

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.